CSL: Result 2016

The new flu vaccine business isn't yet profitable, but antibodies are flying off the shelves.

Ten years ago, CSL was famous for three things: volatile earnings, thin margins and pitiful returns on capital. You would be forgiven for thinking the CSL of today was an entirely different company.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles